RareMed Solutions

Overview

RareMed Solutions is a rare-disease and complex-specialty hub services provider built for manufacturer patient-support programs, combining concierge case management (RareSupport), reimbursement and affordability operations, RareMed Direct non-commercial pharmacy, and the RarePath technology platform. RareMed is independent — outside wholesaler, PBM, and specialty-pharmacy parent ownership.

RareMed is not a conventional commercial specialty pharmacy and not a high-volume scaled hub. It is a high-touch hub partner for products where patient finding, enrollment cleanup, prior authorization support, bridge/free-drug logistics, and ongoing patient follow-up need to be coordinated in one operating model — most relevant for orphan, complex specialty, and cell/gene programs.

Hub Capability Model

The framework below standardizes how Rx Almanac evaluates hub-services capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, RareMed is evaluated as a high-touch rare-disease and complex-specialty hub with non-commercial pharmacy support.

Capability	Buyer should compare	RareMed Solutions readout
Therapy initiation and enrollment intake	Digital and human intake, eConsent, missing-information resolution, provider/patient portals, and clean case creation.	RareSupport teams are positioned around disease-specific patient liaison and case-management work for rare and complex therapies.
Benefits verification and coverage triage	Medical/pharmacy benefit verification, eligibility checks, payer-policy lookup, coverage routing, and speed from referral to actionable case.	Strong fit when a launch needs white-glove coverage discovery and escalation rather than a mostly automated intake queue.
Prior authorization, appeals, and reimbursement casework	PA initiation, payer-specific forms, clinical documentation, appeals, denial management, and field reimbursement handoffs.	Core hub function; validate brand-specific PA staffing, payer escalation paths, and service-level reporting in the RFP.
Affordability, PAP, and copay operations	Copay, free-drug, bridge, foundation, income verification, PAP renewal, and gross-to-net sensitive affordability logic.	Public materials support copay/coupon, financial assistance, and patient-assistance program work. RareMed Direct adds non-commercial dispensing for eligible programs.
Patient engagement and adherence operations	Omnichannel reminders, clinical education, nursing or training escalation, persistence outreach, and patient-facing support quality.	Core rare-disease support. RareSupport teams are positioned around patient liaison work for rare and complex therapies; validate channel cadence, education, persistence outreach, and clinical-escalation rules.
Fulfillment, specialty pharmacy, and distribution coordination	Routing to SPs, non-commercial dispensing, DTP shipment, sample/replacement product, 3PL, and cold-chain handoffs.	RareMed Direct is the important differentiator for manufacturers that need hub plus non-commercial pharmacy in the same operating relationship.
Program reporting, integrations, and governance	Manufacturer dashboards, KPI reporting, CRM/EHR/API integrations, SLA governance, and operating visibility across vendors.	RarePath is the named technology suite. Diligence should focus on data feeds, portal workflows, reporting latency, and integration ownership.

Buyer Fit

• Use-case fit: Rare/orphan, complex specialty, and cell/gene-style launches that need high-touch case management rather than a broad, low-cost hub queue.
• Where it can be strongest: Patient services programs with small or hard-to-reach populations, intensive reimbursement workflows, bridge/PAP needs, and a premium on patient satisfaction.
• Where to validate: Commercial specialty pharmacy network design, payer leverage, and specialty pharmacy routing are separate from RareMed’s core hub/NCP role. Confirm the division of labor with each dispensing pharmacy in the launch network.
• Commercial model: Custom/RFP. Expect program-specific staffing, service levels, data reporting, escalation rules, and transition plans to matter more than a simple per-case price.

Differentiators

• Rare-disease focus: The profile is strongest for orphan and complex specialty programs where patient education, reimbursement cleanup, and persistence work are materially harder than the average specialty launch.
• Independent hub posture: RareMed is positioned outside wholesaler, PBM, and specialty pharmacy parent ownership, which can matter when a manufacturer wants a neutral hub coordinating across multiple channel partners.
• RareMed Direct: The non-commercial pharmacy gives RareMed a tighter operating model for free-drug, bridge, and PAP fulfillment than a hub that must always hand those activities to another vendor.
• RarePath: The named patient-services platform supports manufacturer reporting, portals, workflow management, and analytics. Confirm what is standard versus custom for each brand.
• Service-quality signaling: Public 2025 materials highlight MMIT patient-satisfaction recognition and RareMed’s Specialty Pharmacy Hubs award visibility, which are useful but should be translated into brand-specific SLA and patient-experience metrics during diligence.

RFP Questions

• Which workflows are staffed by RareSupport, which are handled by RareMed Direct, and which stay with the manufacturer’s specialty pharmacy network?
• What are the median and 90th-percentile cycle times for enrollment completion, benefit verification, PA submission, PA approval, bridge shipment, and first commercial fill?
• How does RarePath ingest and reconcile data from specialty pharmacies, field teams, manufacturer CRM systems, and patient-facing portals?
• What reporting is available by payer, geography, provider office, therapy start outcome, abandonment reason, and affordability path?
• What transition plan would RareMed use if the manufacturer migrates an existing patient population from another hub?

Recent Activity

• 2026: RareMed continued to appear in MMIT Specialty Pharmacy Patient Choice Awards coverage for Specialty Pharmacy Hubs.
• November 2025: RareMed was recognized as the fastest-growing company in Pittsburgh by Pittsburgh Business Times Fast 50 coverage.
• September 2025: RareMed expanded its relationship with PTC Therapeutics for Sephience (sepiapterin), including non-commercial pharmacy dispensing and RareSupport patient liaison work for PKU.
• June 2025: RareMed publicized a 100-point patient satisfaction score and related MMIT recognition.
• May 2023: Drug Channels covered RareMed’s expansion from rare-only programs toward rare plus complex prevalent conditions.